和鉑醫藥控股有限公司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
FOOD AND DRUG ADMINISTRATION OF THE UNITED STATES IND CLEARANCE FOR HBM9033 CLINICAL TRIAL INITIATION

This announcement is made by HBM Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the Company has been granted the clearance of Investigational New Drug (the "**IND**") from the Food and Drug Administration of the United States (FDA) to initiate clinical trials in the U.S. for our first antibody drug conjugate ("**ADC**") program HBM9033. This is a Phase I study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of HBM9033 in subjects with advanced solid tumors.

HBM9033 is our first ADC asset that enters into clinical stage. Building on the extensive applications of the HCAb PLUS™ platform in the ADC field, we have established an ecosystem of ADC that synergizes our in-house development with external collaborations. As evidenced by the rapid progress made by our partners and us, we will continuously strengthen our active presence in the ADC field globally.

About HBM9033

HBM9033 is an ADC drug candidate that specifically targets human mesothelin (MSLN), an upregulated tumor associated antigen in various solid tumors, including mesothelioma, ovary cancer, lung cancer, breast cancer, and pancreatic cancers. The fully human monoclonal antibody in HBM9033, generated from the Harbour Mice® platform, binds preferably to membrane bond MSLN over soluble MSLN, which minimizes the interference of the shedding MSLN on the binding and internalization of the membrane bond MSLN. HBM9033 utilizes a tumor specific cleavable linker with a novel topoisomerase inhibitor for improved stability and activity. The unique design for both mAb and linker-payload together has demonstrated the superior potency and safety of HBM9033 in pre-clinical studies. This product was developed by the Company, in collaboration with MediLink Therapeutics. This phase I study is to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of HBM9033 in subjects with advanced solid tumors.

Cautionary Statement: We cannot guarantee that we will be able to successfully develop or ultimately market HBM9033. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 28 August 2023

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Ms. Weiwei Chen as non-executive Director; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Mr. Ka Chi Yau and Dr. Albert R. Collinson as independent non-executive Directors.